Related by context. Frequent words. (Click for all words.) 72 Inc Therapeutic Competitors 66 Detailed Product 66 Presents Positive 65 Cholesterol Drug 64 Files Shelf Registration Statement 63 Patient Enrollment 63 FDA Accepts 63 OSI Pharma 62 Drug Candidate 62 Exploit collaboration 62 Develop Novel 62 Equipment Deals 62 Generic Version 61 Completes Enrollment 61 Genentech Roche 61 Completes Tender Offer 61 Product Pipeline 61 Report companiesandmarkets.com adds 61 Drug Pipeline 61 Clinical Trial Results 61 Announces Initiation 61 RNAi Therapeutics 61 Teva Pharma 61 www.companiesandmarkets.com 61 Paladin Labs 61 submitted Marketing Authorization 61 NASDAQ SHPGY 60 Transcept Pharmaceuticals 60 Explore Strategic Alternatives 60 Blood Thinner 60 Strategic Analysis Profile 60 Nasdaq AMLN 60 Inc SWOT Analysis 60 Idera Pharmaceuticals 60 Extends Tender Offer 60 www.gsk.com 60 Q1 Profit Surges 60 Earnings Scorecard 60 Co MRK 59 Nasdaq BIIB 59 Patent Lawsuit 59 Cancer Vaccines 59 FDA Clears 59 SWOT Analysis companiesandmarkets.com adds 59 Kuvan R 59 Q4 Profit Surges 59 Patent Infringement Case 59 Stockholders Approve Merger 59 Q3 Loss Widens 59 Significantly Increases 59 Small Molecule 59 Q2 Loss Narrows 59 Company PicShot 59 Espicom Business Intelligence 59 Signs Licensing Agreement 59 Q3 Loss Narrows 59 Aarkstore Enterprise 59 Q4 Loss Narrows 59 Cetrorelix 59 Lowers Guidance 59 Tibotec Pharmaceuticals 59 Portola Pharmaceuticals 59 Panzem R 59 Announces Publication 59 Receives FDA Clearance 58 Pulmonary Arterial Hypertension 58 Q1 Loss Narrows 58 Licensing Agreements 58 Q2 Profit Surges 58 Autoimmune Disease 58 BioSante Pharmaceuticals 58 Phase III Clinical Trial 58 Q1 Loss Widens 58 Pivotal Study 58 Progenics Pharmaceuticals 58 Q2 Loss Widens 58 Positive Opinion 58 Pirfenidone 58 Biogenerics 58 Copegus R 58 Q4 Loss Widens 58 ICOS Corporation 58 SWOT Framework Analysis 58 Inc. Nasdaq SEPR 58 Summarizes 58 Pivotal Phase III 58 Phase III Trial 58 Secures Financing 58 Commercialization Agreement 58 Reports Positive 58 Vytorin combines 58 Significantly Reduces 58 Drug Makers 57 Patent Covering 57 Diet Pill 57 Shareholder Letter 57 Backs FY# EPS 57 Q3 Profit Surges 57 DecisionBase 57 Generic Drug 57 Announces Stockholder Approval